Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HINT1 | P49773 | 6/20 | 0.59 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.58 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.58 |
| ▸ | HPGD | P15428 | 2/20 | 0.56 |
| ▸ | NT5E | P21589 | 1/20 | 0.54 |
| ▸ | GSK3A | P49840 | 2/20 | 0.53 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.53 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.53 |
| ▸ | PNP | P00491 | 2/20 | 0.51 |
| ▸ | TGM2 | P21980 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15060652 | 0.93 | HINT1 (0.61) | HINT1TAS1R3TAS1R1HPGDNT5E | |
| SCHEMBL8205186 | 0.92 | HPGD (0.58) | HINT1TAS1R3TAS1R1HPGDNT5E | |
| SCHEMBL13597930 | 0.92 | HPGD (0.58) | HINT1TAS1R3TAS1R1HPGDNT5E | |
| SCHEMBL3812199 | 0.92 | HPGD (0.58) | HINT1TAS1R3TAS1R1HPGDNT5E | |
| SCHEMBL15061595 | 0.91 | HINT1 (0.67) | HINT1TAS1R3TAS1R1NT5EGSK3A | |
| SCHEMBL2582792 | 0.90 | HPGD (0.56) | HINT1TAS1R3TAS1R1HPGDNT5E | |
| SCHEMBL12300426 | 0.89 | HPGD (0.61) | HINT1TAS1R3TAS1R1HPGDNT5E | |
| SCHEMBL16360143 | 0.89 | HPGD (0.61) | HINT1TAS1R3TAS1R1HPGDNT5E | |
| SCHEMBL3713950 | 0.89 | HPGD (0.61) | HINT1TAS1R3TAS1R1HPGDNT5E | |
| SCHEMBL18512866 | 0.89 | HPGD (0.61) | HINT1TAS1R3TAS1R1HPGDNT5E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12618064-B2 | Acetylated ribonucleic acids and uses thereof | HELIX NANOTECHNOLOGIES INC (US) | 2026-05-05 | — | — | US | disclosed |
| US-20250346888-A1 | PROMOTER PROXIMAL SEQUENCES AND USES THEREOF FOR RNA MANUFACTURING | HELIX NANOTECHNOLOGIES INC (US) | 2025-11-13 | — | — | US | disclosed |
| US-20250270299-A1 | METHODS OF USING COMPOSITIONS COMPRISING SBI DOMAINS | HELIX NANOTECHNOLOGIES INC | 2025-08-28 | — | — | US | disclosed |
| US-20250129364-A1 | ACETYLATED RIBONUCLEIC ACIDS AND USES THEREOF | HELIX NANOTECHNOLOGIES INC | 2025-04-24 | — | — | US | disclosed |
| EP-4519280-A2 | ACETYLATED RIBONUCLEIC ACIDS AND USES THEREOF | Helix Nanotechnologies Inc (US) | 2025-03-12 | — | — | EP | disclosed |
| US-12215317-B2 | Acetylated ribonucleic acids and uses thereof | HELIX NANOTECHNOLOGIES INC (US) | 2025-02-04 | — | — | US | disclosed |
| US-20230383287-A1 | ACETYLATED RIBONUCLEIC ACIDS AND USES THEREOF | HELIX NANOTECHNOLOGIES INC | 2023-11-30 | — | — | US | disclosed |
| US-20230383287-A1 | ACETYLATED RIBONUCLEIC ACIDS AND USES THEREOF | HELIX NANOTECHNOLOGIES INC | 2023-11-30 | — | — | US | disclosed |
| US-20230383287-A1 | ACETYLATED RIBONUCLEIC ACIDS AND USES THEREOF | HELIX NANOTECHNOLOGIES INC | 2023-11-30 | — | — | US | disclosed |
| WO-2023215516-A2 | ACETYLATED RIBONUCLEIC ACIDS AND USES THEREOF | HELIX NANOTECHNOLOGIES, INC. (US) | 2023-11-09 | — | — | WO | disclosed |
| WO-2008112826-A1 | METHOD AND PROCESS FOR THE PRODUCTION OF MULTI-COATED RECOGNITIVE AND RELEASING SYSTEMS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2008-09-18 | — | — | WO | disclosed |
| EP-0670845-A1 | PROCESS FOR THE PREPARATION OF FLUDARABINE PHOSPHATE FROM GUANOSINE | SCHERING AKTIENGESELLSCHAFT (DE) | 1995-09-13 | — | — | EP | disclosed |
| WO-1994012514-A1 | PROCESS FOR THE PREPARATION OF FLUDARABINE PHOSPHATE FROM GUANOSINE | SCHERING AKTIENGESELLSCHAFT (DE) | 1994-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12215317-B2 | Acetylated ribonucleic acids and uses thereof | NSUN2, NSUN3, ADAR | HINT1 757/4885TAS1R3 3515/4885TAS1R1 3915/4885 |
| US-20230383287-A1 | ACETYLATED RIBONUCLEIC ACIDS AND USES THEREOF | NSUN2, NSUN3, ADAR | HINT1 757/4885TAS1R3 3515/4885TAS1R1 3915/4885 |
| US-12618064-B2 | Acetylated ribonucleic acids and uses thereof | RNMT, TRDMT1, TRMT1L | HINT1 1406/4885TAS1R3 3082/4885TAS1R1 3264/4885 |
| US-20250346888-A1 | PROMOTER PROXIMAL SEQUENCES AND USES THEREOF FOR RNA MANUFACTURING | RNGTT, NSUN2, CPSF6 | HINT1 1377/4885TAS1R3 3931/4885TAS1R1 4355/4885 |
| US-20250270299-A1 | METHODS OF USING COMPOSITIONS COMPRISING SBI DOMAINS | C1QBP, SSB, SARNP | HINT1 396/4885TAS1R3 4781/4885TAS1R1 4777/4885 |
| US-20250129364-A1 | ACETYLATED RIBONUCLEIC ACIDS AND USES THEREOF | NSUN2, NSUN3, ADAR | HINT1 757/4885TAS1R3 3515/4885TAS1R1 3915/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.